Colonic Gastric Polypectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Polypectomy is the endoscopic removal of polyps — abnormal tissue growths that protrude from the lining of the gastrointestinal tract — from either the colon (colonic polypectomy, performed during colonoscopy) or the stomach (gastric polypectomy, performed during gastroscopy/upper endoscopy). The removal of colorectal polyps is one of the most important preventive interventions in gastroenterology, as the majority of colorectal cancers arise from adenomatous polyps through the well-characterised adenoma-carcinoma sequence over 5–15 years. Detection and removal of these precancerous lesions during colonoscopy reduces colorectal cancer incidence by approximately 70–90%.

Colonic polyps are classified by morphology (pedunculated — on a stalk, or sessile — flat/broad-based), size (diminutive <5mm, small 6–9mm, large ≥10mm), and histology (adenomatous, hyperplastic, serrated, inflammatory). Adenomatous polyps are the clinically significant precancerous type, further classified as tubular, tubulovillous, or villous adenomas based on their microscopic architecture. The risk of malignant transformation increases with polyp size (particularly ≥10mm), villous histology, and high-grade dysplasia.

Gastric polyps are less clinically significant than colorectal polyps in most cases: fundic gland polyps (the most common type, accounting for 70–80% of gastric polyps) are benign and typically require no treatment unless causing symptoms. Adenomatous gastric polyps and hyperplastic polyps > 1 cm are associated with a small cancer risk and require removal. All polyps removed endoscopically should be submitted for histological examination to guide surveillance intervals and additional treatment decisions.

Colonic adenomatous polyps are the primary cancer prevention indication for colonic polypectomy. Detection and removal of tubular, tubulovillous, and villous adenomas interrupts the adenoma-carcinoma sequence and significantly reduces the lifetime risk of colorectal cancer. Advanced adenomas (size ≥10mm, villous features, or high-grade dysplasia) are at highest risk of malignant transformation and are priority removal targets. Serrated polyps — including sessile serrated lesions (SSLs) and traditional serrated adenomas (TSAs) — are recognised as alternative precancerous lesions accounting for 20–30% of interval cancers (cancers developing after a negative colonoscopy) and are now specifically targeted in surveillance guidelines.

Gastric polyps treated endoscopically include gastric adenomas (premalignant, particularly in the setting of gastric intestinal metaplasia or H. pylori infection), large hyperplastic polyps causing bleeding or obstruction, and large fundic gland polyps in patients on long-term proton pump inhibitor therapy where reduction of size is required. Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP) are hereditary syndromes causing hundreds to thousands of colorectal polyps requiring repeated endoscopic polypectomy and ultimately prophylactic colectomy.

Patients undergoing diagnostic colonoscopy or gastroscopy who are found to have polyps are candidates for polypectomy at the same endoscopic session. Most colonic polyps identified during colonoscopy are removed immediately — 'resect and discard' for diminutive hyperplastic-appearing polyps, or formal polypectomy for adenomatous-appearing lesions. Patients are eligible for polypectomy if they are not taking anticoagulants that cannot be safely withheld, do not have known bleeding disorders, and bowel preparation is adequate.

Anticoagulation management before polypectomy follows specific guidance: aspirin alone does not require interruption for most polypectomy. Warfarin, direct oral anticoagulants (DOACs), and thienopyridines (clopidogrel) increase bleeding risk and are typically withheld for 5–7 days before large polypectomy with specialist guidance on bridging. Large complex sessile lesions may require referral to a specialist EMR/ESD centre rather than immediate removal at a general endoscopy unit, to ensure complete en-bloc resection with appropriate margins.

Cold snare polypectomy (CSP) uses a wire snare without electrical current to transect and remove polyps up to 9–10mm. It is the preferred technique for small to medium polyps as it has a lower complication rate than hot snare polypectomy (no electrosurgical current eliminates risk of delayed haemorrhage and post-polypectomy electrocoagulation syndrome). Cold biopsy forceps removal is used for diminutive polyps (<5mm), though cold snare is increasingly replacing forceps even for small polyps due to higher complete resection rates.

Hot snare polypectomy uses diathermy current through the snare wire to both cut and coagulate, providing haemostasis during resection. It is used for larger pedunculated polyps (≥20mm) where haemostasis from the stalk is needed, and for villous adenomas where en-bloc resection with cauterisation of the base reduces recurrence. Endoscopic mucosal resection (EMR) is used for large sessile or flat polyps (10–30mm): a cushion of saline or sodium hyaluronate is injected beneath the polyp into the submucosal space, lifting it away from the deeper muscle wall, and the polyp is then snared and removed in piecemeal fashion. Endoscopic submucosal dissection (ESD) uses a needle-knife electrosurgical device to dissect beneath the polyp in the submucosal plane, achieving en-bloc resection of lesions up to 50–60mm. ESD has higher complete resection rates but also higher complication rates (perforation 2–5%) than EMR.

Polypectomy during colonoscopy is one of the most effective cancer prevention interventions available. The National Polyp Study demonstrated a 76–90% reduction in colorectal cancer incidence compared to historical controls following colonoscopy with complete polyp removal. The sustained colonoscopy effect (NordICC trial, 2022) showed a 31% reduction in colorectal cancer incidence in the randomised colonoscopy group in a European population, confirming the population-level preventive effect.

Complete resection of adenomatous polyps removes the precancerous lesion before malignant transformation can occur. For patients with advanced adenomas (≥10mm, villous, HGD), polypectomy at colonoscopy followed by appropriate 3-year surveillance colonoscopy detects the majority of metachronous advanced adenomas before they progress to cancer. Gastric polypectomy prevents gastric cancer from polyps with malignant potential, particularly adenomatous gastric polyps associated with H. pylori-induced intestinal metaplasia, where cure of H. pylori and polyp removal is a comprehensive cancer prevention strategy.

Polypectomy is a safe procedure with low complication rates in experienced hands. Bleeding is the most common complication, occurring in 0.5–2% of colonoscopic polypectomies. Immediate intraoperative bleeding occurs during or immediately after resection and is managed with injection of dilute adrenaline, haemostatic clips, or thermal coagulation. Delayed haemorrhage (occurring 2–14 days post-polypectomy) occurs in approximately 0.5–1% and is more common after large polypectomy, hot snare use, and in anticoagulated patients.

Colonic perforation is the most serious complication of polypectomy, occurring in 0.1–0.5% of polypectomies overall and 1–2% for large EMR and 2–5% for ESD. Perforation may be detected intraoperatively (immediate repair with endoscopic clips, may avoid surgery) or delayed (presents with peritonism 24–72 hours post-procedure, often requiring emergency surgical repair). Post-polypectomy syndrome (coagulation syndrome) — fever, localised abdominal pain, and elevated white cell count without perforation — occurs in 0.5–1% after hot polypectomy, representing superficial thermal injury to the colonic wall, and is managed conservatively with antibiotics. Polyp recurrence at the polypectomy site occurs in 10–30% of large EMR sites, requiring surveillance and re-treatment.

After colonic polypectomy, patients are typically discharged the same day or after a short observation period. A clear liquid diet for the rest of the polypectomy day and then a low-fibre diet for 2–5 days (depending on polyp size and technique) reduces irritation to the polypectomy site. Vigorous physical activity is restricted for 1–2 weeks after large polypectomy. Anticoagulant medications can be restarted 48–72 hours after large polypectomy.

Surveillance colonoscopy intervals after polypectomy are risk-stratified by the British Society of Gastroenterology (BSG), European Society of Gastrointestinal Endoscopy (ESGE), and American guidelines: patients with 1–2 small (<10mm) tubular adenomas are returned to population screening at 5–10 years; those with 3–4 adenomas or one ≥10mm or one with HGD are surveilled at 3 years; patients with 5+ adenomas or SSLs ≥10mm or traditional serrated adenomas are surveilled at 1–3 years. High-risk patients (FAP, Lynch syndrome) require annual colonoscopy.

In the United States, colonoscopy with polypectomy costs USD 2,000–4,000 including endoscopy facility fees, sedation, and pathology. Multiple polypectomies or complex EMR/ESD procedures cost more. NHS colonoscopy with polypectomy in the UK is provided free to eligible patients through the Bowel Cancer Screening Programme and symptomatic referral. Annual costs of colonoscopy surveillance in the US exceed USD 10 billion.

Medical tourism for diagnostic colonoscopy and polypectomy is available at very significant cost savings: at private hospitals in India, colonoscopy with polypectomy costs USD 150–500; in Thailand USD 300–700; in Turkey USD 200–500; in Malaysia USD 200–400. These centres have gastroenterologists with advanced endoscopy training and modern video endoscopy equipment. Patients travelling abroad for colonoscopy should ensure pathology results are shared with their home physician for surveillance planning.

CT colonography (virtual colonoscopy) using computed tomography can detect colonic polyps ≥6mm without sedation or bowel instrumentation, but it cannot remove polyps — a significant limitation meaning colonoscopy is required when polyps are detected. It is an alternative screening tool for patients unable to tolerate conventional colonoscopy.

Capsule colonoscopy (a swallowed camera in a pill) has been developed as an alternative to conventional colonoscopy and is validated for patients who decline or cannot tolerate optical colonoscopy, though polypectomy is still required if polyps are found. Stool-based tests including faecal immunochemical test (FIT) and multi-target stool DNA tests (Cologuard) are population screening tools that reduce the colonoscopy burden by pre-selecting higher-risk individuals, but they are not substitutes for colonoscopy with polypectomy in patients with confirmed adenomas.